Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2006-04-26 Interim / Quarterly Rep…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
PHARMING ANNOUNCES FIRST QUARTER 2006 RESULTS-Reports on solid cash position and broadening product pipeline
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Pharming Group NV's financial results for the first quarter ended March 31, 2006. It includes comprehensive financial data such as consolidated balance sheet, income statement, and cash flow statement, along with management commentary on financial performance, product development, and corporate activities. The presence of actual financial statements and substantive financial analysis for a quarterly period indicates this is a quarterly financial report. The document is not merely an earnings release (which would be shorter and less detailed), nor is it an annual report or an announcement of a report publication. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2006
2006-04-26 English
DNage, Loders Croklaan, BG Medicine en Erasumus MC kondigen samenwerking aan op het gebied van type II diabetes.
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaboration agreement among DNage, Loders Croklaan, BG Medicine, and Erasmus MC to develop products and biomarkers for type II diabetes. It includes background information on the companies involved and mentions a planned acquisition of DNage by Pharming. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a partnership and future plans, not a financial report, audit, or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a general corporate announcement about collaboration and investment plans, which best fits under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2006-04-24 Dutch
DNage, Loders Croklaan, BG Medicine en Erasumus MC kondigen samenwerking aan op het gebied van type II diabetes.
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaboration agreement between DNage, Lipid Nutrition, BG Medicine, Erasmus MC, and Pharming in the field of type II diabetes research. It includes background information on the companies involved and details about the grant funding and future commercialization plans. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not an annual report, earnings release, or any form of financial report. It is a corporate announcement about a research collaboration and acquisition intent. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate news, which corresponds to Regulatory Filings (RNS).
2006-04-24 Dutch
Pharming announces acquisition of DNage B.V.
M&A Activity Classification · 95% confidence The document is a press release announcing Pharming Group N.V.'s agreement to acquire DNage B.V., detailing the terms of the acquisition, strategic rationale, background information on both companies, and future expectations. It does not contain financial statements, audit information, or detailed financial results. It is not a regulatory filing, earnings release, or management report. The content focuses on the announcement of a merger/acquisition transaction, including share consideration and warrants, which fits the definition of M&A Activity filings.
2006-03-24 English
Pharming announces acquisition of DNage B.V.
M&A Activity Classification · 100% confidence The document is a press release announcing the acquisition of DNage B.V. by Pharming Group N.V. It details the transaction terms, strategic rationale, background on both companies, and management changes related to the acquisition. There are no financial statements, quarterly or annual results, or regulatory filings such as 10-K or interim reports. The content focuses on a corporate transaction (acquisition) and related business development. Therefore, the document fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2006-03-24 English
PHARMING CONFIRMS POSITIVE OUTLOOK FOR rhC1INH
Regulatory Filings Classification · 95% confidence The document is a press release from Pharming Group N.V. dated February 24, 2006, discussing the positive outlook for their lead product rhC1INH in Phase III clinical trials. It provides background on the disease, the company, and future expectations including profitability timelines. There are no financial statements, regulatory forms, or detailed financial data presented. The document is a corporate announcement about clinical trial progress and business outlook rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate update or press release about product development and outlook. Given the content and length (4146 characters), it is best classified under Regulatory Filings (RNS) as a general regulatory announcement or corporate update that does not fit other specific categories.
2006-02-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.